Modulation of Gut Microbial Diversity through Non-Pharmaceutical Approaches to Treat Schizophrenia

Int J Mol Sci. 2022 Feb 27;23(5):2625. doi: 10.3390/ijms23052625.

Abstract

Schizophrenia (SCZ) is a psychotic syndrome with well-defined signs and symptoms but indecisive causes and effective treatment. Unknown underpinning reasons and no cure of the disease profoundly elevate the risk of illness. Gut microbial dysbiosis related metabolic dysfunction is providing a new angle to look at the potential causes and treatment options for schizophrenia. Because of the number of side effects, including gut dysbiosis, of traditional antipsychotic drugs, new alternative therapeutic options are under consideration. We propose that non-pharmacotherapy using biotherapeutic products could be a potent treatment to improve cognitive impairment and other symptoms of schizophrenia. Use of live microorganisms (probiotics), fibers (prebiotics), and polyphenols alone or in a mixture can maintain gut microbial diversity and improve the two-way relationship of the gut microbiota and the central nervous system. Fiber and polyphenol induced management of gut microbiota may positively influence the gut-brain axis by increasing the level of brain-derived neurotrophic factors involved in schizophrenia. Furthermore, we endorse the need for comprehensive clinical assessment and follow-up of psychobiotic (pro and prebiotics) treatment in mental illness to estimate the level of target recovery and disability reduction in schizophrenia.

Keywords: antipsychotics; gut microbiota; gut–brain axis; neurotransmitters; polyphenols; prebiotics; probiotics; psychobiotics; schizophrenia.

Publication types

  • Review

MeSH terms

  • Brain
  • Dysbiosis
  • Gastrointestinal Microbiome*
  • Humans
  • Prebiotics
  • Probiotics* / therapeutic use
  • Schizophrenia* / drug therapy

Substances

  • Prebiotics